SCHEMBL3662924

SCHEMBL3662924

CCCC1(c2ccccc2)NC(=O)N(CC(=O)c2ccc(NC(=O)Nc3ccccc3F)cc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
KDM4A O75164 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
LMNA P02545 2/20 0.49
HTT P42858 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
PKM P14618 1/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47
MEN1 O00255 1/20 0.46
KDM4E B2RXH2 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3657145 0.85 MEN1 (0.52) KMT2ALMNAHTTMAPTSMN1; SMN2
SCHEMBL3663347 0.85 KMT2A (0.58) KMT2AKDM4AHDAC6LMNAHTT
SCHEMBL4121157 0.83 KMT2A (0.55) KMT2AKDM4AHDAC6LMNAHTT
SCHEMBL3658033 0.82 MEN1 (0.49) KMT2AHTTMAPTSMN1; SMN2NPC1
SCHEMBL3660786 0.81 KMT2A (0.57) KMT2AHDAC6LMNAHTTMAPT
SCHEMBL3664165 0.79 KMT2A (0.52) KMT2AHDAC6LMNAHTTMAPT
SCHEMBL3663231 0.79 HDAC6 (0.58) KMT2AKDM4AHDAC6LMNAHTT
SCHEMBL3660389 0.79 HDAC6 (0.58) KMT2AKDM4AHDAC6LMNAHTT
SCHEMBL3662888 0.77 KMT2A (0.61) KMT2AHDAC6LMNAHTTMAPT
SCHEMBL2983179 0.77 NPC1 (0.49) KMT2AHTTMAPTGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 KMT2A 2020/4885KDM4A 3348/4885HDAC6 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.